Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Washington
With
Merck Sharp & Dohme LLC
The study will be conducted at the UW Primary Infection Clinic and the UW AIDS Clinical Trials Unit. Secondary objectives will characterize safety, tolerability, plasma HIV-1 RNA and CD4+ T-cell values. The 3-drug HAART will be chosen and provided by the subject.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Acute or Early HIV-1 infection
HIV-1 RNA \> or equal to 500 copies/mL
Acceptable safety lab results (specified in protocol)
Negative pregnancy test for females
Willingness to use contraception (for females of reproductive potential
You may not be if
Prior receipt of investigational HIV-1 vaccine
Use of immunomodulators other than systemic steroids within 30 days before entry
Serious medical or psychiatric illness that would interfere with study participation
Active drug or alcohol use that would interfere with study participation
Allergy/hypersensitivity to raltegravir
Pre- or Post-exposure prophylaxis for the exposure that led to HIV-1 acquisition
Pregnancy or breastfeeding
History of malignancy (other than localized squamous cell or basal cell cancer of the skin)
